Cancer and Tumor Biomarker-based Assay Market
Cancer and Tumor Biomarker-based Assay Market Size and Share Forecast Outlook 2025 to 2035
Cancer and tumor biomarker-based assay market is projected to grow from USD 12.1 billion in 2025 to USD 33.5 billion by 2035, at a CAGR of 10.7%. Breast Cancer will dominate with a 23.4% market share, while genetic/genomic biomarkers will lead the biomarker type segment with a 66.3% share.
FREE CustomizationCancer and Tumor Biomarker-based Assay Market Forecast and Outlook 2025 to 2035
The global cancer and tumor biomarker-based assay market is projected to grow from USD 12.1 billion in 2025 to approximately USD 33.5 billion by 2035, recording an absolute increase of USD 21.4 billion over the forecast period. This translates into a total growth of 176.9%, with the market forecast to expand at a compound annual growth rate (CAGR) of 10.7% between 2025 and 2035.
The overall market size is expected to grow by nearly 2.8X during the same period, supported by increasing prevalence of cancer globally, rising adoption of precision oncology and companion diagnostics, and increasing focus on early detection and personalized treatment approaches across the global healthcare and diagnostics sectors.
Quick Stats for Cancer and Tumor Biomarker-based Assay Market
- Cancer and Tumor Biomarker-based Assay Market Value (2025): USD 12.1 billion
- Cancer and Tumor Biomarker-based Assay Market Forecast Value (2035): USD 33.5 billion
- Cancer and Tumor Biomarker-based Assay Market Forecast CAGR: 10.7%
- Leading Cancer Type in Cancer and Tumor Biomarker-based Assay Market: Breast Cancer (23.4%)
- Key Growth Regions in Cancer and Tumor Biomarker-based Assay Market: Asia Pacific, North America, and Europe
- Key Players in Cancer and Tumor Biomarker-based Assay Market: F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Guardant Health, Exact Sciences Corp., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Sysmex Corp., Abbott, bioMérieux SA
Between 2025 and 2030, the cancer and tumor biomarker-based assay market is projected to expand from USD 12.1 billion to USD 20.2 billion, resulting in a value increase of USD 8.1 billion, which represents 37.9% of the total forecast growth for the decade. This phase of development will be shaped by rising demand for liquid biopsy technologies, increasing applications in genomic profiling and targeted therapy selection segments, and growing penetration in emerging oncology diagnostics markets. Diagnostic laboratories and healthcare providers are expanding their biomarker testing capabilities to address the growing demand for precision oncology solutions in various cancer types and treatment applications.
From 2030 to 2035, the market is forecast to grow from USD 20.2 billion to USD 33.5 billion, adding another USD 13.3 billion, which constitutes 62.1% of the overall ten-year expansion. This period is expected to be characterized by the expansion of comprehensive genomic profiling platforms, the integration of artificial intelligence-based diagnostic systems, and the development of novel biomarker assays for emerging cancer indications. The growing adoption of companion diagnostics and personalized medicine requirements will drive demand for ultra-high performance biomarker-based assays with enhanced sensitivity specifications and consistent clinical utility characteristics.
Between 2020 and 2025, the cancer and tumor biomarker-based assay market experienced robust expansion, driven by increasing recognition of biomarker testing importance in oncology care and growing acceptance of molecular diagnostics in complex cancer management processes. The market developed as oncologists and pathologists recognized the need for advanced biomarker assay systems to guide treatment decisions and improve overall patient outcomes.
Research and development activities have emphasized the importance of next-generation sequencing and liquid biopsy technologies in achieving better diagnostic accuracy and treatment personalization in oncology applications, establishing a strong foundation for the anticipated accelerated growth trajectory through 2035.
Cancer and Tumor Biomarker-based Assay Market Key Takeaways
| Metric | Value |
|---|---|
| Estimated Value in (2025E) | USD 12.1 billion |
| Forecast Value in (2035F) | USD 33.5 billion |
| Forecast CAGR (2025 to 2035) | 10.7% |
Why is the Cancer and Tumor Biomarker-based Assay Market Growing?
Market expansion is being supported by the increasing prevalence of cancer worldwide and the corresponding need for advanced biomarker-based diagnostic solutions in oncology applications across global healthcare and laboratory operations. Modern oncologists and pathologists are increasingly focused on sophisticated biomarker assays that can improve treatment selection, enable early cancer detection, and enhance patient stratification while meeting stringent clinical validation requirements. The proven clinical utility of biomarker-based assays in various cancer management applications makes them an essential component of comprehensive precision oncology strategies and personalized treatment programs.
The growing emphasis on healthcare industry transformation and precision medicine optimization is driving demand for ultra-efficient biomarker-based assays that meet stringent analytical specifications and clinical requirements for oncology applications. Clinicians' preference for reliable, high-performance diagnostic platforms that can ensure consistent treatment guidance outcomes is creating opportunities for innovative biomarker assay technologies and customized oncology solutions. The rising influence of clinical practice guidelines and regulatory approval pathways for companion diagnostics is also contributing to increased adoption of validated biomarker-based assays across different cancer types and therapeutic applications requiring advanced molecular diagnostic technology.
The cancer and tumor biomarker-based assay market represents a specialized high-growth opportunity, expanding from USD 12.1 billion in 2025 to USD 33.5 billion by 2035 at a 10.7% CAGR. As healthcare providers prioritize diagnostic accuracy, treatment personalization, and clinical outcomes in complex cancer management processes, biomarker assay systems have evolved from supplementary testing approaches to essential components enabling precision diagnosis, therapy selection optimization, and comprehensive patient care across oncology operations and specialized diagnostic applications. The convergence of cancer burden increase, growing genomic testing adoption, specialized companion diagnostics development, and personalized medicine requirements creates significant momentum in demand across all major global oncology markets.
Segmental Analysis
The market is segmented by cancer type, biomarker type, end use, and region. By cancer type, the market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, and ovarian cancer & others. Based on biomarker type, the market is categorized into genetic/genomic biomarkers, protein biomarkers, epigenetic biomarkers, and others.
By end use, the market is divided into hospitals & cancer centers, diagnostic laboratories, and others. Regionally, the market is divided into Asia Pacific, North America, Europe, Latin America, Middle East & Africa.
Why does Breast Cancer account for a Dominant Market Share?
The breast cancer segment is projected to account for 23.4% of the cancer and tumor biomarker-based assay market in 2025, with HER2, BRCA1/2, and PIK3CA assays representing approximately 41.0% of the breast cancer segment, reaffirming its position as the category's dominant cancer type.
Oncologists increasingly recognize the critical importance of biomarker testing for breast cancer treatment selection, particularly for targeted therapies and immunotherapy applications. This cancer type addresses both diagnostic requirements and therapeutic decision-making considerations while providing actionable molecular information across diverse patient populations.
This segment forms the foundation of most precision oncology protocols for solid tumor applications, as it represents the most established and clinically validated biomarker testing paradigm in the oncology field. Clinical utility standards and extensive validation studies continue to strengthen confidence in breast cancer biomarker assays among oncologists and pathology laboratories.
With increasing recognition of the treatment-optimization requirements in breast cancer management operations, biomarker-based testing systems align with both clinical effectiveness and patient outcome goals, making them the central growth driver of comprehensive breast cancer care strategies across domestic and international healthcare markets.
How Does Genetic/Genomic Biomarkers Type Achieve 66.3% Market Leadership?
Genetic/genomic biomarkers are projected to represent 66.3% of cancer and tumor biomarker-based assay demand in 2025, with comprehensive genomic profiling (CGP) accounting for approximately 35.0% of the genetic biomarker segment, underscoring its role as the primary biomarker category driving market adoption and growth.
Healthcare providers recognize that genomic biomarker requirements, including complex mutational analysis, gene expression profiling, and multi-gene panel testing, often require advanced sequencing technologies that standard diagnostic approaches cannot adequately provide. Genetic/genomic biomarkers offer enhanced diagnostic precision and therapeutic selection guidance in precision oncology applications.
The segment is supported by the growing adoption of next-generation sequencing globally, requiring sophisticated bioinformatics systems, and the increasing recognition that genomic biomarker testing can improve treatment outcomes and clinical decision-making. Additionally, oncologists are increasingly adopting evidence-based treatment guidelines that recommend specific genomic biomarker testing for optimal therapy selection.
As understanding of cancer genomics advances and targeted therapy options become more numerous, comprehensive genomic profiling and molecular biomarker testing will continue to play a crucial role in precision oncology strategies within the global cancer care market.
Why are Hospitals & Cancer Centers the Preferred Points of Contact for Cancer and Tumor Biomarker-based Assays?
Hospitals & cancer centers are projected to represent 44.3% of cancer and tumor biomarker-based assay demand in 2025, with liquid biopsy platforms accounting for approximately 32.0% of the hospitals & cancer centers segment, underscoring its role as the leading end use segment driving market adoption and growth.
Healthcare administrators recognize that comprehensive cancer center requirements, including integrated diagnostic services, multidisciplinary tumor boards, and longitudinal patient monitoring, often require on-site biomarker testing capabilities that external laboratory services alone cannot adequately provide. Hospitals & cancer centers offer streamlined diagnostic workflows and rapid turnaround times for treatment-critical biomarker testing.
The segment is supported by the growing complexity of cancer care delivery, requiring sophisticated molecular diagnostic infrastructure, and the increasing recognition that in-house biomarker testing can improve clinical workflow efficiency and patient care coordination. Additionally, cancer centers are increasingly implementing precision oncology programs that require comprehensive biomarker testing capabilities for optimal treatment delivery.
As cancer treatment protocols become more personalized and time-sensitive treatment decisions increase, integrated biomarker testing within hospitals & cancer centers will continue to play a vital role in comprehensive oncology care strategies within the global healthcare system.
What are the Drivers, Restraints, and Key Trends of the Cancer and Tumor Biomarker-based Assay Market?
The cancer and tumor biomarker-based assay market is advancing rapidly due to increasing recognition of precision medicine importance and growing demand for molecular diagnostic solutions across the oncology and healthcare sectors.
The industry faces challenges, including high testing costs and reimbursement limitations in certain markets, potential for complex result interpretation requiring specialized expertise, and concerns about standardization consistency across different testing platforms and methodologies. Innovation in liquid biopsy technologies and artificial intelligence-based diagnostic interpretation continues to influence product development and market expansion patterns.
Expansion of Liquid Biopsy Technologies and Non-invasive Testing Approaches
The growing adoption of liquid biopsy platforms is enabling the development of more sophisticated minimally invasive biomarker detection systems that can provide comprehensive tumor profiling through simple blood draws.
Specialized diagnostic laboratories offer advanced liquid biopsy assays, including circulating tumor DNA (ctDNA) analysis and circulating tumor cell (CTC) detection that are particularly important for treatment monitoring and early recurrence detection applications.
Advanced liquid biopsy technologies provide serial testing capabilities that can track treatment response and detect minimal residual disease while minimizing patient burden compared to traditional tissue biopsy approaches.
Integration of Artificial Intelligence and Next-Generation Sequencing Platforms
Modern diagnostic organizations are incorporating artificial intelligence technologies such as machine learning-based variant interpretation, automated quality control systems, and integrated bioinformatics pipelines to enhance biomarker assay accuracy and clinical reporting.
These technologies improve diagnostic precision, enable comprehensive genomic profiling, and provide better integration between molecular testing and clinical decision support throughout the cancer care continuum.
Advanced AI platforms also enable identification of novel biomarker patterns and prediction of treatment response, supporting personalized oncology approaches and enhancing overall patient care outcomes through data-driven treatment selection.
Analysis of the Cancer and Tumor Biomarker-based Assay Market by Key Country
| Country | CAGR (2025-2035) |
|---|---|
| India | 11.9% |
| China | 11.6% |
| USA | 10.8% |
| Germany | 9.7% |
| Japan | 9.4% |
| UK | 8.9% |
| Brazil | 8.6% |
The cancer and tumor biomarker-based assay market is experiencing exceptional growth globally, with India leading at an 11.9% CAGR through 2035, driven by rapid genomic testing infrastructure development and government oncology missions. China follows at 11.6%, supported by domestic NGS providers and Healthy China 2030 initiative. USA shows 10.8% growth, representing liquid biopsy and companion diagnostics expansion.
Germany demonstrates 9.7% growth, emphasizing adoption under EU IVDR compliance and pharma collaborations. Japan records 9.4% growth with expansion of AI-based molecular assays for gastric and lung cancers. UK records 8.9% growth with NHS Genomic Medicine Service and early detection programs, while Brazil shows 8.6% growth, representing public hospital oncology testing programs and IHC infrastructure development.
How is India Demonstrating Exceptional Market Potential with Genomic Testing Infrastructure?
Revenue from cancer and tumor biomarker-based assays in India is projected to exhibit exceptional growth with a CAGR of 11.9% through 2035, driven by rapid genomic testing infrastructure development and government oncology missions supporting comprehensive cancer care. The country's expanding cancer diagnostic capabilities and growing availability of next-generation sequencing facilities are creating significant opportunities for biomarker assay adoption across tertiary cancer centers and specialized oncology hospitals.
Major international diagnostics companies and domestic molecular pathology laboratories are establishing comprehensive testing networks to serve the growing population of oncologists requiring advanced biomarker testing across breast, lung, and colorectal cancer applications throughout India's major metropolitan regions.
The Indian government's strategic emphasis on cancer control programs and affordable diagnostics is driving substantial investments in molecular testing infrastructure and oncology workforce development. This policy support, combined with the country's large cancer patient population and increasing health insurance coverage for diagnostics, creates a favorable environment for biomarker-based assay market development.
Indian oncology centers are increasingly adopting international treatment guidelines that mandate biomarker testing, with genomic profiling and companion diagnostics representing key components in this precision oncology transformation.
What Drives China's Exceptional Market Growth with Domestic NGS Providers?
Revenue from cancer and tumor biomarker-based assays in China is expanding at a CAGR of 11.6%, supported by domestic NGS providers, Healthy China 2030 initiative, and growing emphasis on precision oncology across the country's extensive healthcare network. The country's rapidly developing molecular diagnostics sector and increasing implementation of standardized cancer treatment protocols are driving demand for comprehensive biomarker testing solutions in both public and private oncology facilities.
International diagnostics leaders and domestic biotechnology companies are establishing advanced sequencing centers to serve the enormous demand for cancer biomarker testing while supporting the country's national cancer control objectives. China's oncology sector continues to benefit from government healthcare reform initiatives, expanding cancer screening programs, and substantial investment in genomic medicine infrastructure.
The country's focus on reducing cancer mortality and improving treatment access is driving adoption of advanced biomarker testing technologies and companion diagnostics. Growing prevalence of lung cancer and increasing adoption of targeted therapies are creating opportunities for comprehensive genomic profiling across oncology departments in major hospitals throughout Beijing, Shanghai, and Guangzhou, while regulatory reforms supporting innovative diagnostics facilitate increased availability of cutting-edge biomarker assay platforms.
How Does USA lead with Liquid Biopsy and Companion Diagnostics?
Revenue from cancer and tumor biomarker-based assays in USA is projected to exhibit strong growth with a CAGR of 10.8% through 2035, driven by liquid biopsy technology adoption and expanding companion diagnostics utilization across precision oncology applications. The country's advanced molecular diagnostics infrastructure and well-established regulatory framework for companion diagnostics are creating a favorable environment for innovative biomarker assay commercialization. American oncology practices and cancer centers are increasingly implementing liquid biopsy platforms for treatment monitoring and resistance detection applications.
The USA market benefits from robust healthcare reimbursement for molecular testing, strong pharmaceutical-diagnostic collaboration ecosystems, and leading academic medical centers driving clinical validation studies. Liquid biopsy and companion diagnostics segments are experiencing rapid growth as targeted therapy approvals increase and precision oncology becomes standard of care. Medicare and commercial payer coverage expansions for comprehensive genomic profiling support widespread adoption of multi-gene panel testing and ctDNA analysis across community and academic oncology settings.
What Drives Germany's Growth with EU IVDR Compliance?
Germany's market expansion benefits from implementation of EU In Vitro Diagnostic Regulation (IVDR) compliance requirements and strong pharmaceutical-diagnostic collaborations supporting companion diagnostics development. The country maintains a 9.7% CAGR through 2035, driven by rigorous quality standards and integration of molecular diagnostics into clinical pathways.
German healthcare system emphasizes evidence-based medicine and high-quality diagnostic testing, creating demand for validated biomarker assays meeting stringent regulatory requirements. Pharmaceutical companies collaborate extensively with diagnostic developers to support drug development and precision medicine initiatives. Growing adoption of comprehensive genomic profiling in university hospitals and specialized oncology centers supports market expansion, while IVDR compliance drives quality improvements across molecular pathology laboratories.
How Does Japan Expand AI-based Molecular Assays for Cancer Detection?
Japan demonstrates robust market development with a 9.4% CAGR through 2035, distinguished by expansion of AI-based molecular assays for gastric and lung cancer detection. The country's advanced healthcare technology sector and high cancer screening rates are driving adoption of innovative biomarker testing approaches.
Japanese oncology centers focus on technology integration and precision diagnostics, creating demand for AI-enhanced biomarker interpretation platforms and automated testing systems. The market benefits from government support for cancer genomic medicine and growing reimbursement for comprehensive gene panel testing. Emphasis on early detection and treatment personalization for prevalent cancers like gastric and lung cancer drives continued investment in advanced molecular diagnostic technologies.
What Drives UK's Growth with NHS Genomic Medicine Service?
UK's market expansion benefits from NHS Genomic Medicine Service implementation and early cancer detection programs driving systematic adoption of biomarker testing. The country maintains an 8.9% CAGR through 2035, driven by national genomics strategy and coordinated cancer care pathways.
British healthcare system is implementing comprehensive genomic testing programs through NHS infrastructure, creating standardized access to biomarker-based assays across cancer centers. Early detection initiatives and targeted screening programs increase biomarker testing volumes. Growing emphasis on precision oncology within NHS cancer treatment protocols supports expanded molecular testing utilization and improved integration of genomic data into clinical decision-making.
How Does Brazil Demonstrate Growth with Public Hospital Oncology Programs?
Brazil demonstrates solid market development with an 8.6% CAGR through 2035, driven by public hospital oncology testing programs and expanding immunohistochemistry (IHC) infrastructure. The country's growing cancer care capacity in public healthcare system creates opportunities for biomarker testing adoption.
Brazilian oncology departments are implementing systematic biomarker testing protocols in public hospitals, supported by government cancer control initiatives. IHC infrastructure expansion enables wider access to protein biomarker testing for breast cancer and other solid tumors. Growing availability of molecular pathology services in regional cancer centers supports increased biomarker testing utilization across diverse patient populations.
Competitive Landscape of the Cancer and Tumor Biomarker-based Assay Market
The cancer and tumor biomarker-based assay market is characterized by competition among established diagnostics manufacturers, molecular pathology companies, and biotechnology firms focused on delivering accurate, clinically validated, and comprehensive biomarker testing solutions.
Companies are investing in technology platform development, clinical evidence generation, strategic partnerships with pharmaceutical companies and cancer centers, and regulatory approval processes to deliver innovative, reliable, and actionable biomarker assay products that meet stringent oncology and regulatory requirements. Product differentiation, clinical utility demonstration, and commercialization strategies are central to strengthening product portfolios and market presence across global precision oncology operations.
F. Hoffmann-La Roche Ltd. leads the market with approximately 17.2% market share, offering comprehensive tissue and liquid biopsy platforms with focus on companion diagnostics and comprehensive genomic profiling for targeted therapy selection. Thermo Fisher Scientific Inc. provides specialized next-generation sequencing solutions and Oncomine assays with emphasis on comprehensive cancer panel testing.
Illumina Inc. focuses on advanced sequencing platforms and TruSight oncology panels serving clinical laboratories and research institutions globally. QIAGEN delivers established sample preparation and PCR-based biomarker testing solutions with strong presence in molecular pathology laboratories.
Guardant Health operates with focus on liquid biopsy technology and ctDNA analysis for treatment monitoring and minimal residual disease detection. Exact Sciences Corp. provides specialized cancer screening and monitoring assays including Oncotype DX gene expression tests. Bio-Rad Laboratories Inc. specializes in digital PCR platforms and quality control materials for molecular testing.
Agilent Technologies Inc. delivers comprehensive genomic workflow solutions and companion diagnostic development services. Sysmex Corp., Abbott, and bioMérieux SA provide specialized automation platforms, immunoassay systems, and molecular diagnostic solutions, serving diverse oncology testing requirements across hospital laboratories, diagnostic centers, and specialized cancer testing facilities globally.
Key Players in the Cancer and Tumor Biomarker-based Assay Market
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- QIAGEN
- Guardant Health
- Exact Sciences Corp.
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc.
- Sysmex Corp.
- Abbott
- bioMérieux SA
Scope of the Report
| Items | Values |
|---|---|
| Quantitative Units (2025) | USD 12.1 Billion |
| Cancer Type | Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer & Others |
| Biomarker Type | Genetic/Genomic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Others (Metabolomic / Immune Markers) |
| End Use | Hospitals & Cancer Centers, Diagnostic Laboratories, Others (Research Labs, Clinics) |
| Regions Covered | Asia Pacific, North America, Europe, Latin America, Middle East & Africa |
| Countries Covered | China, USA, Germany, Japan, India, Brazil, UK and 40+ countries |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Guardant Health, Exact Sciences Corp., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Sysmex Corp., Abbott, bioMérieux SA |
| Additional Attributes | Dollar sales by cancer type and biomarker type, regional demand trends, competitive landscape, oncologist preferences for specific biomarker assays, integration with precision oncology treatment pathways, innovations in liquid biopsy and genomic profiling technologies, clinical validation, and companion diagnostics development |
Cancer and Tumor Biomarker-based Assay Market by Segments
-
Cancer Type :
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Ovarian Cancer & Others
-
Biomarker Type :
- Genetic/Genomic Biomarkers
- Protein Biomarkers
- Epigenetic Biomarkers
- Others
-
End Use :
- Hospitals & Cancer Centers
- Diagnostic Laboratories
- Others
-
Region :
-
Asia Pacific
- China
- India
- Japan
- South Korea
- ASEAN
- Australia & New Zealand
- Rest of Asia Pacific
-
North America
- USA
- Canada
- Mexico
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Nordic
- BENELUX
- Rest of Europe
-
Latin America
- Brazil
- Argentina
- Chile
- Rest of Latin America
-
Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkey
- South Africa
- Other African Countries
- Rest of Middle East & Africa
-
Table of Content
- Executive Summary
- Global Market Outlook
- Demand to side Trends
- Supply to side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2020 to 2024 and Forecast, 2025 to 2035
- Historical Market Size Value (USD Million) Analysis, 2020 to 2024
- Current and Future Market Size Value (USD Million) Projections, 2025 to 2035
- Y to o to Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2020 to 2024 and Forecast 2025 to 2035
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Cancer Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Cancer Type, 2020 to 2024
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Cancer Type, 2025 to 2035
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Ovarian Cancer & Others
- Y to o to Y Growth Trend Analysis By Cancer Type, 2020 to 2024
- Absolute $ Opportunity Analysis By Cancer Type, 2025 to 2035
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Biomarker Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Biomarker Type, 2020 to 2024
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Biomarker Type, 2025 to 2035
- Genetic/Genomic Biomarkers
- Protein Biomarkers
- Epigenetic Biomarkers
- Others
- Y to o to Y Growth Trend Analysis By Biomarker Type, 2020 to 2024
- Absolute $ Opportunity Analysis By Biomarker Type, 2025 to 2035
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By End Use
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End Use, 2020 to 2024
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End Use, 2025 to 2035
- Hospitals & Cancer Centers
- Diagnostic Laboratories
- Others
- Y to o to Y Growth Trend Analysis By End Use, 2020 to 2024
- Absolute $ Opportunity Analysis By End Use, 2025 to 2035
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2020 to 2024
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2025 to 2035
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- USA
- Canada
- Mexico
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- Latin America Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- Western Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- Eastern Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- East Asia Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- China
- Japan
- South Korea
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- South Asia and Pacific Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- Middle East & Africa Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Cancer Type
- By Biomarker Type
- By End Use
- By Country
- Market Attractiveness Analysis
- By Country
- By Cancer Type
- By Biomarker Type
- By End Use
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Canada
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Mexico
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Brazil
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Chile
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Germany
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- UK
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Italy
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Spain
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- France
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- India
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- China
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Japan
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- South Korea
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Russia
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Poland
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Hungary
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- South Africa
- Pricing Analysis
- Market Share Analysis, 2024
- By Cancer Type
- By Biomarker Type
- By End Use
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Cancer Type
- By Biomarker Type
- By End Use
- Competition Analysis
- Competition Deep Dive
- F. Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- QIAGEN
- Guardant Health
- Exact Sciences Corp.
- Bio-Rad Laboratories Inc.
- Agilent Technologies Inc.
- Sysmex Corp.
- Abbott
- bioMérieux SA
- F. Hoffmann-La Roche Ltd.
- Competition Deep Dive
- Assumptions & Acronyms Used
- Research Methodology
List Of Table
- Table 1: Global Market Value (USD Million) Forecast by Region, 2020 to 2035
- Table 2: Global Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 3: Global Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 4: Global Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 5: North America Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 6: North America Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 7: North America Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 8: North America Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 9: Latin America Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 10: Latin America Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 11: Latin America Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 12: Latin America Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 13: Western Europe Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 14: Western Europe Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 15: Western Europe Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 16: Western Europe Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 17: Eastern Europe Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 18: Eastern Europe Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 19: Eastern Europe Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 20: Eastern Europe Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 21: East Asia Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 22: East Asia Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 23: East Asia Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 24: East Asia Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 25: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 26: South Asia and Pacific Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 27: South Asia and Pacific Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 28: South Asia and Pacific Market Value (USD Million) Forecast by End Use, 2020 to 2035
- Table 29: Middle East & Africa Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 30: Middle East & Africa Market Value (USD Million) Forecast by Cancer Type, 2020 to 2035
- Table 31: Middle East & Africa Market Value (USD Million) Forecast by Biomarker Type, 2020 to 2035
- Table 32: Middle East & Africa Market Value (USD Million) Forecast by End Use, 2020 to 2035
List Of Figures
- Figure 1: Global Market Pricing Analysis
- Figure 2: Global Market Value (USD Million) Forecast 2020 to 2035
- Figure 3: Global Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 4: Global Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 5: Global Market Attractiveness Analysis by Cancer Type
- Figure 6: Global Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 7: Global Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 8: Global Market Attractiveness Analysis by Biomarker Type
- Figure 9: Global Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 10: Global Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 11: Global Market Attractiveness Analysis by End Use
- Figure 12: Global Market Value (USD Million) Share and BPS Analysis by Region, 2025 and 2035
- Figure 13: Global Market Y to o to Y Growth Comparison by Region, 2025 to 2035
- Figure 14: Global Market Attractiveness Analysis by Region
- Figure 15: North America Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 16: Latin America Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 17: Western Europe Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 18: Eastern Europe Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 19: East Asia Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 20: South Asia and Pacific Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 21: Middle East & Africa Market Incremental Dollar Opportunity, 2025 to 2035
- Figure 22: North America Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 23: North America Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 24: North America Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 25: North America Market Attractiveness Analysis by Cancer Type
- Figure 26: North America Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 27: North America Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 28: North America Market Attractiveness Analysis by Biomarker Type
- Figure 29: North America Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 30: North America Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 31: North America Market Attractiveness Analysis by End Use
- Figure 32: Latin America Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 33: Latin America Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 34: Latin America Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 35: Latin America Market Attractiveness Analysis by Cancer Type
- Figure 36: Latin America Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 37: Latin America Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 38: Latin America Market Attractiveness Analysis by Biomarker Type
- Figure 39: Latin America Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 40: Latin America Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 41: Latin America Market Attractiveness Analysis by End Use
- Figure 42: Western Europe Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 43: Western Europe Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 44: Western Europe Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 45: Western Europe Market Attractiveness Analysis by Cancer Type
- Figure 46: Western Europe Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 47: Western Europe Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 48: Western Europe Market Attractiveness Analysis by Biomarker Type
- Figure 49: Western Europe Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 50: Western Europe Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 51: Western Europe Market Attractiveness Analysis by End Use
- Figure 52: Eastern Europe Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 53: Eastern Europe Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 54: Eastern Europe Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 55: Eastern Europe Market Attractiveness Analysis by Cancer Type
- Figure 56: Eastern Europe Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 57: Eastern Europe Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 58: Eastern Europe Market Attractiveness Analysis by Biomarker Type
- Figure 59: Eastern Europe Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 60: Eastern Europe Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 61: Eastern Europe Market Attractiveness Analysis by End Use
- Figure 62: East Asia Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 63: East Asia Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 64: East Asia Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 65: East Asia Market Attractiveness Analysis by Cancer Type
- Figure 66: East Asia Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 67: East Asia Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 68: East Asia Market Attractiveness Analysis by Biomarker Type
- Figure 69: East Asia Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 70: East Asia Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 71: East Asia Market Attractiveness Analysis by End Use
- Figure 72: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 73: South Asia and Pacific Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 74: South Asia and Pacific Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 75: South Asia and Pacific Market Attractiveness Analysis by Cancer Type
- Figure 76: South Asia and Pacific Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 77: South Asia and Pacific Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 78: South Asia and Pacific Market Attractiveness Analysis by Biomarker Type
- Figure 79: South Asia and Pacific Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 80: South Asia and Pacific Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 81: South Asia and Pacific Market Attractiveness Analysis by End Use
- Figure 82: Middle East & Africa Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 83: Middle East & Africa Market Value Share and BPS Analysis by Cancer Type, 2025 and 2035
- Figure 84: Middle East & Africa Market Y to o to Y Growth Comparison by Cancer Type, 2025 to 2035
- Figure 85: Middle East & Africa Market Attractiveness Analysis by Cancer Type
- Figure 86: Middle East & Africa Market Value Share and BPS Analysis by Biomarker Type, 2025 and 2035
- Figure 87: Middle East & Africa Market Y to o to Y Growth Comparison by Biomarker Type, 2025 to 2035
- Figure 88: Middle East & Africa Market Attractiveness Analysis by Biomarker Type
- Figure 89: Middle East & Africa Market Value Share and BPS Analysis by End Use, 2025 and 2035
- Figure 90: Middle East & Africa Market Y to o to Y Growth Comparison by End Use, 2025 to 2035
- Figure 91: Middle East & Africa Market Attractiveness Analysis by End Use
- Figure 92: Global Market - Tier Structure Analysis
- Figure 93: Global Market - Company Share Analysis
- FAQs -
How big is the cancer and tumor biomarker-based assay market in 2025?
The global cancer and tumor biomarker-based assay market is estimated to be valued at USD 12.1 billion in 2025.
What will be the size of cancer and tumor biomarker-based assay market in 2035?
The market size for the cancer and tumor biomarker-based assay market is projected to reach USD 33.5 billion by 2035.
How much will be the cancer and tumor biomarker-based assay market growth between 2025 and 2035?
The cancer and tumor biomarker-based assay market is expected to grow at a 10.7% CAGR between 2025 and 2035.
What are the key product types in the cancer and tumor biomarker-based assay market?
The key product types in cancer and tumor biomarker-based assay market are breast cancer , lung cancer , colorectal cancer , prostate cancer and ovarian cancer & others.
Which biomarker type segment to contribute significant share in the cancer and tumor biomarker-based assay market in 2025?
In terms of biomarker type, genetic/genomic biomarkers segment to command 66.3% share in the cancer and tumor biomarker-based assay market in 2025.
Cancer and Tumor Biomarker-based Assay Market